Drugging the myofibroblast: a new approach to treating fibrosis.
Location: United States, Massachusetts, Cambridge
Total raised: $105M
Founded date: 2019
Investors 3
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| - | Ono Ventur... | onoventure... |
| 23.03.2023 | GIMV | gimv.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.03.2023 | - | $105M | Sofinnova ... |
Mentions in press and media 8
| Date | Title | Description |
| 07.08.2024 | Mediar Therapeutics Initiates Second Clinical Program in Portfolio of Novel First-In-Class Antibodies Designed to Halt Fibrosis | First cohort of participants dosed in Phase 1 trial evaluating safety and tolerability of MTX-474, a human IgG1 antibody designed to neutralize EphrinB2 signaling Phase 1 study for MTX-463, an antibody neutralizing WISP1-mediated fibrotic s... |
| 04.04.2023 | Latest Updates of 6 Viva's Portfolio Companies | HONG KONG, April 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies... |
| 15.03.2023 | Mediar Therapeutics Raises $105M in Funding | Mediar Therapeutics, a Cambridge, MA-based biotechnology company, raised $105M in funding. The round was led by Novartis Venture Fund and Sofinnova Partners with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol ... |
| 17.03.2021 | Mediar Therapeutics : Adds New Investors As It Advances Anti-Fibrotic Treatments | Mediar Therapeutics today announced the completion of a seed extension funding round and welcomed Pfizer Ventures and Ono Venture Investment (OVI) as new syndicate members. Mediar, a discovery-stage company developing new treatments for fib... |
| 17.03.2021 | Mediar Therapeutics Adds New Investors As It Advances Anti-Fibrotic Treatments | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 17, 2021-- Mediar Therapeutics today announced the completion of a seed extension funding round and welcomed Pfizer Ventures and Ono Venture Investment (OVI) as new syndicate members. Mediar, a discove... |
| 17.03.2021 | Mediar Therapeutics Adds New Investors As It Advances Anti-Fibrotic Treatments | CAMBRIDGE, Mass.–(BUSINESS WIRE)–March 17, 2021– Mediar Therapeutics today announced the completion of a seed extension funding round and welcomed Pfizer Ventures and Ono Venture Investment (OVI) as new syndicate members. Mediar, a discover... |
| - | Ono Venture Investment makes a follow-on investment in Mediar Therapeutics. (Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies) | - |
| - | Mediar Therapeutics | “Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.” |